Clopidogrel and the reduced-function CYP2C19 genetic variant: a limited piece of the overall therapeutic puzzle

JAMA. 2010 Oct 27;304(16):1839-40. doi: 10.1001/jama.2010.1566.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Acute Coronary Syndrome / therapy*
  • Angioplasty, Balloon, Coronary
  • Aryl Hydrocarbon Hydroxylases / genetics*
  • Cardiovascular Diseases / diagnosis*
  • Clopidogrel
  • Cytochrome P-450 CYP2C19
  • Genotype
  • Humans
  • Patient Selection
  • Pharmacogenetics
  • Platelet Aggregation Inhibitors / adverse effects*
  • Platelet Aggregation Inhibitors / therapeutic use
  • Risk
  • Stents
  • Ticlopidine / adverse effects
  • Ticlopidine / analogs & derivatives*
  • Ticlopidine / therapeutic use

Substances

  • Platelet Aggregation Inhibitors
  • Clopidogrel
  • Aryl Hydrocarbon Hydroxylases
  • CYP2C19 protein, human
  • Cytochrome P-450 CYP2C19
  • Ticlopidine